Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13614
UPID:
MTMR2_HUMAN
Alternative names:
Phosphatidylinositol-3,5-bisphosphate 3-phosphatase; Phosphatidylinositol-3-phosphate phosphatase
Alternative UPACC:
Q13614; A6NN98; Q9UPS9
Background:
Myotubularin-related protein 2, also known as Phosphatidylinositol-3,5-bisphosphate 3-phosphatase, plays a crucial role in lipid metabolism by dephosphorylating phosphoinositides. It specifically targets phosphatidylinositol 3-phosphate and phosphatidylinositol 3,5-bisphosphate, essential for cellular processes. This protein stabilizes SBF2/MTMR13 in peripheral nerves, indicating its significance in nerve function.
Therapeutic significance:
Linked to Charcot-Marie-Tooth disease 4B1, a demyelinating disorder, Myotubularin-related protein 2's dysfunction underscores its therapeutic potential. Understanding its role could lead to targeted treatments for this and related peripheral nervous system diseases.